Marshall Wace North America’s Adicet Bio ACET Stock Holding History

Marshall Wace North America’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-278	Closed	-$212K	–	1102
2019 Q1	$212K	Buy	278 +258	+1,290%	+$234K	﹤0.01%	974
2018 Q4	$19K	Buy	+20	New	+$26.3K	﹤0.01%	1396
2018 Q2	–	Sell	-489	Closed	-$525K	–	1345
2018 Q1	$525K	Buy	+489	New	+$897K	﹤0.01%	1140

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's ACET Position: Q2 2019 in Review

Marshall Wace North America sold out of Adicet Bio (ACET) in Q2 2019, closing a stake of 278 shares — an estimated $212K sold.

Marshall Wace North America first reported a position in ACET in Q1 2018 and held it in 3 quarters. The position peaked at $525K in Q1 2018. 48 funds tracked by Wall St. Rank hold ACET as of Q2 2019.

Marshall Wace North America reported no remaining Adicet Bio position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 278 Adicet Bio shares in Q2 2019, an estimated $212K.
Marshall Wace North America first reported a position in Adicet Bio in Q1 2018 and held it in 3 quarters.
Marshall Wace North America's Adicet Bio position peaked at $525K in Q1 2018.
48 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.